Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod combined with methotrexate for remission or reversal of bone erosion in rheumatoid arthritis
ChiCTR1900021686Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iguratimod and methotrexate in rheumatoid arthritis (RA), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Joint evaluation. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
iguratimodmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR1900021686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021686.